HeyJaredAdam Feuerstein
STORY ANGLES - Focuses on market impact: Highlights stock-moving events, commercial potential, and valuation changes in biotech deals and trials. - Emphasizes regulatory implications: Explores FDA decisions, approvals, and rejections, often delving into internal agency dynamics.
- Indexed articles, last 90 days
- 2
- Latest publication
- Jul 29, 2026
- Outlet visibility, for STAT News
- Top 100K sites
- Earliest in this view
- Jul 28, 2026
Latest articles
STAT+: In the biotech industry, a most-wanted fugitive was long hiding in plain sight (opens the original)
Read excerpt
Ronald Fischer, a most-wanted fugitive, was long hiding in the biotech industry in plain sight, and using an alias more extensively than has been previously reported.
STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment (opens the original)
Read excerpt
ProMIS Neurosciences is trying to design a safer amyloid-clearing drug for Alzheimer's. Early results suggest it might be on to something.
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 100K sites
For STAT News, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.